SeaStar Medical (ICU) Expected to Announce Earnings on Thursday

SeaStar Medical (NASDAQ:ICU) will likely be issuing its Q4 2025 results before the market opens on Thursday, March 26th. Analysts expect SeaStar Medical to post earnings of ($0.97) per share and revenue of $0.2220 million for the quarter. Individuals are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Wednesday, March 25, 2026 at 4:30 PM ET.

SeaStar Medical Trading Down 5.2%

ICU stock opened at $2.35 on Thursday. The firm has a 50 day moving average of $2.49 and a 200-day moving average of $4.32. SeaStar Medical has a 12 month low of $2.20 and a 12 month high of $25.70. The firm has a market capitalization of $8.91 million, a P/E ratio of -0.14 and a beta of -1.04.

Institutional Trading of SeaStar Medical

A number of hedge funds have recently made changes to their positions in the stock. XTX Topco Ltd grew its position in SeaStar Medical by 395.4% in the second quarter. XTX Topco Ltd now owns 60,983 shares of the company’s stock worth $26,000 after acquiring an additional 48,674 shares in the last quarter. Jane Street Group LLC purchased a new stake in SeaStar Medical during the fourth quarter valued at about $30,000. Finally, Millennium Management LLC bought a new stake in SeaStar Medical during the third quarter worth about $102,000. 1.69% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several analysts have issued reports on ICU shares. Weiss Ratings reissued a “sell (e+)” rating on shares of SeaStar Medical in a report on Thursday, January 22nd. Maxim Group set a $6.00 price target on shares of SeaStar Medical in a report on Thursday, February 12th. Finally, Wall Street Zen upgraded SeaStar Medical to a “hold” rating in a research report on Saturday, January 10th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat.com, SeaStar Medical presently has an average rating of “Sell” and a consensus target price of $6.00.

About SeaStar Medical

SeaStar Medical, Inc (NASDAQ: ICU) is a medical device company focused on the development and commercialization of cerebral embolic protection systems for patients undergoing transcatheter aortic valve replacement (TAVR) procedures. The company’s mission is to reduce the risk of stroke and other neurologic events associated with structural heart interventions by capturing or deflecting embolic debris that can travel to the brain during catheter-based therapies.

The company’s flagship product, TriGUARD® 3, is a next-generation embolic deflection device designed to provide coverage of all three cerebral vessels during TAVR.